Unlocking the Power of mRNA: Pioneering a New Era in Therapeutic Innovation and Precision Medicine

References

1. Kumar S. Thakur K. Sharma B. Bhardwaj T.R. Prasad D.N. Singh R.K. Recent advances in vaccine development for the treatment of emerging infectious diseases. Indian J Pharm Educ Res 2019 53 3 343 354 10.5530/ijper.53.3.68
   [Google Scholar]
2. Parhiz H. Atochina-Vasserman E.N. Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 2024 403 10432 1192 1204 10.1016/S0140‑6736(23)02444‑3 38461842
   [Google Scholar]
3. Niazi S.K. Affordable mRNA novel proteins, recombinant protein conversions, and biosimilars—advice to developers and regulatory agencies. Biomedicines 2025 13 1 97 10.3390/biomedicines13010097 39857681
   [Google Scholar]
4. Androsavich J.R. Frameworks for transformational breakthroughs in RNA-based medicines. Nat. Rev. Drug Discov. 2024 23 6 421 444 10.1038/s41573‑024‑00943‑2 38740953
   [Google Scholar]
5. Weber J.S. Carlino M.S. Khattak A. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024 403 10427 632 644 10.1016/S0140‑6736(23)02268‑7 38246194
   [Google Scholar]
6. Kis Z. Rizvi Z. Weaver H. Athanasiou C. Shah N. Scaling up mRNA COVID-19 vaccine production: An analysis of potential challenges and opportunities for technology transfer. Vaccine 2021 39 34 4780 4788 10.1016/j.vaccine.2021.07.020
   [Google Scholar]
7. Wouters O.J. Shadlen K.C. Salcher-Konrad M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 2021 397 10278 1023 1034 10.1016/S0140‑6736(21)00306‑8 33587887
   [Google Scholar]
8. Muik A. Garralda E. Altintas I. Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors. Cancer Discov. 2022 12 5 1248 1265 10.1158/2159‑8290.CD‑21‑1345 35176764
   [Google Scholar]
9. Thermostable mRNA formulations Nat Biotechnol 2023 41 678 85
   [Google Scholar]
10. PLGA nanoparticles for cystic fibrosis Sci Adv 2023 9 12 eadg3445
    [Google Scholar]
11. Hassan J. Haigh C. Ahmed T. Uddin M.J. Das D.B. Potential of microneedle systems for COVID-19 vaccination: Current trends and challenges. Pharmaceutics 2022 14 5 1066 10.3390/pharmaceutics14051066
    [Google Scholar]
12. CleanCap® technology Nat Biotechnol 2020 38 4 472 7 33257862
    [Google Scholar]
13. Niazi S.K. The United States Food and Drug Administration’s platform technology designation to expedite the development of drugs. Pharmaceutics 2024 16 7 918 10.3390/pharmaceutics16070918 39065616
    [Google Scholar]
14. Moosavi S.G. Rahiman N. Jaafari M.R. Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases. Journal of Controlled Release 2025 113641 [https://doi.org/10.1016/j.jconrel.2025.113641]
    [Google Scholar]
15. Casmil I.C. Jin J. Won E.J. The advent of clinical self-amplifying RNA vaccines. Mol. Ther. 2025 33 6 2565 2582 10.1016/j.ymthe.2025.03.060 40186353
    [Google Scholar]